Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of citicoline sodium injection in China. Welcome to wholesale bulk high quality citicoline sodium injection for sale here from our factory. Good service and reasonable price are available.
Citicoline Sodium Injection is a nucleoside derivative coenzyme drug used for the treatment of acute traumatic brain injury and postoperative consciousness disorders. Its main component is the monosodium salt of choline cytidine diphosphate, which has stable chemical properties and is a colorless and clear liquid at room temperature. It needs to be stored in a light shielded and sealed environment.
This drug reduces cerebral vascular resistance, increases cerebral blood flow, promotes brain substance metabolism, and improves cerebral circulation. At the same time, it can enhance the ability of the brainstem reticular activating system and pyramidal system, improve motor paralysis, and have a positive effect on promoting brain ability recvery and awakening. Pharmacokinetic studies have shown that drugs rapidly enter the bloodstream after injection, with some entering brain tissue through the blood-brain barrier. The concentration in damged brain tissue is significantly higher than that in normal brain tissue, and the residence time is prolonged, which is beneficial for targeted treatment.
Additional information of chemical compound:
Our Product
Citicoline sodium +. COA
Acute traumatic brain injury: including brain contusion and laceration, skull fracture, etc., can shorten coma time and promote recvery. Citicoline Sodium Injection data shows that combined conventional treatmen can shorten the duration of coma by 40% -50%.
Postoperative consciousnes disorders after brain surgery, such as brain tumor resection and intracranial hematoma clearance, can enhance pyramidal tract ability and improve limb motor paralysis.
Cerebrovascular accident sequelae: including cerebral infarction and cerebral hemorrhage recvery period, can promote neurological ability recvery and improve activities of daily living (ADL) scores. Research shows that after 6 weeks of continuous mediation, ADL scores increased by 35% -40% compared to baseline.
Expand application areas
Toxic encephalopathy: Brain damge caused by carbon monoxide poisoning, organophosphate pesticide poisoning, etc., can alleviate oxidative stress damge and promote brain cell membrane repair.
Assisted treatmen for neurodegenerative diseases: cognitive dysfunction syndrome (CCDS) in elderly dogs and cats, Alzheimer's disease, etc., can delay cognitive decline and improve memory. Preliminary experiments have shown that after 6 months of combined treatmen with mecobalamin, cognitive ability scores improved by 40%.
Secondary nerve injury caused by intervertebral disc herniation: By promting the expression of nerve growth factor (NGF), synaptic remodeling and nerve regeneration are supported.
Usage, dosage and administration plan
Intravenous drip:
Dosage: 0.25-0.5g per day, diluted with 5% or 10% glucose injection and slowly dripped.
Course of treatmen: Every 5-10 days is a course of treatmen, which can be adjusted according to the condition.
Caution: High doses should not be used during the acute phase of cerebral hemorrhage to avoid exacerbating the risk of bleeding.
Intravenous injection:
Dosage: 100-200mg (0.1-0.2g) each time, directly injected or diluted before injection.
Applicable scenarios: Emergency situations that require rapid action, such as delayed postoperative recvery.
Intramuscular injection:
Dosage: 0.1-0.3g per day, divided into 1-2 injections.
Attention: Due to the strong irritant effect of the mediation, intramuscular injection is generally not recommended; If needed, the injection site should be changed frequently to avoid local hardening.
Citicolin Sodum, as a multi-target neuroprotective agent, has shown significant efficacy in the treatmen of acute traumatic brain injury, cerebrovascular accidents, and neurodegenerative diseases. It promotes brain ability recvery through mechanims such as improving brainless blood flow, repairing cell membranes, and regulating neurotransmitters, and has high safety.
Citicoline sodium injection is a nucleoside derivative coenzyme drug, with its core component being the monosodium salt of choline cytidine diphosphate. As a classic drug in the field of neuroprotection, its mechanim of action involves synergistic effects of multiple targets and pathways, covering key aspects such as brainless hemodynamic regulation, neurotransmitter balance, cell membrane repair, and energy metabolis optimization.
Molecular Mechanim of Action: Multi target Collaborative Neural Protection Network
1. Cerebrovascular dynamics regulation: reduce resistance and increase perfusion
Sodum phosphatidylcholin reduces brainless vascular resistance by inhibiting the influx of calcium ions into vascular smooth muscle cells, lowering brainless vascular tension. This effect is manifested in animal experiments as an increase of approximately 15% -20% in brainless artery diameter and a 25% -30% increase in brainless blood flow (CBF). Clinical studies have shown that after administration to patients with acute traumatic brain injury, there is a significant increase in brain tissue oxygen partial pressure (PbO ₂), indicating improvement in brainless perfusion.
Key evidence:
A randomized controlled trial (RCT) involving 80 patients with acute brainless infarction showed that the combination therapy of phosphatidylcholin sodum and thrombolysis can increase brainless blood flow by 32%, while the thrombolysis group alone only increased by 18% (p<0.01).
In animal models, drugs can reverse ischemia induced brainless vasospasm and restore vascular autoregulation ability.
2. Neurotransmitter system regulation: dual regulation of acetylcholine and dopamine
Sodum phosphatidylcholin, as a precursor of choline, can penetrate the blood-brain barrier and convert into acetylcholine (ACh) in neurons, enhancing cholinergic neurotransmission. Meanwhile, its metabolite cytidine diphosphate (CDP) can promote dopamine (DA) synthesis and improve dopaminergic neurological ability.Action path:
Cholinergic pathway: drugs → choline → acetyl CoA+choline acetyltransferase (ChAT) → ACh → synaptic cleft → activation of M1/N receptors → improvement of cognitive and motor function.
Dopamine pathway: CDP → UDP → dopamine precursor → tyrosine hydroxylase (TH) activation → increased DA synthesis → relief of bradykinesia and depression symptoms.
Clinical significance:
In the Parkinson's disease model, phosphatidylcholin sodum can increase striatal DA content by 22% and significantly improve motor symptom scores (UPDRS-III decreased by 18%).
After treatmen, the ACh level of Alzheimer's disease patients increased to 1.5 times the baseline value, and the MMSE score improved by 2.3 points (p=0.03).
3. Cell membrane repair and activation of phospholipid metabolis
Sodum phosphatidylcholin is a key methylated donor for the synthesis of phosphatidylcholin (PC), which can promote the renewal of nerve cell membrane phospholipids, enhance membrane fluidity and stability. The mechanim includes:
Methylation reaction: Provides methyl groups (CH3), catalyzes the conversion of phosphatidylethanolamine (PE) to PC, and repairs damged cell membranes.
Antioxidant effect: Inhibits lipid peroxidation, reduces malondialdehyde (MDA) production, and protects neurons from oxidative stress damge.
Experimental data:
After drug treatmen, the PC content of neurons cultured in vitro increased by 40% and the membrane fluidity increased by 25% (detected by fluorescence polarization method).
In a rat model of brainless ischemia, phosphatidylcholin sodum reduced MDA levels in the hippocampus by 35% and increased superoxide dismutase (SOD) activity by 22%.
4. Induction of nerve growth factor (NGF) synthesis
Sodum phosphatidylcholin can upregulate NGF gene expression, promote NGF synthesis and release, thereby activating TrkA receptors and initiating neuroprotective signaling pathways (such as PI3K/Akt, MAPK/ERK). This effect is particularly significant in the repair of peripheral nerve injuries.
Research case:
In a rat model of sciatic nerve injury, the drug increased the expression of NGF mRNA by three times and accelerated axonal regeneration by 40%.
Clinical observations have shown that the improvement rate of nerve conduction velocity (NCV) in patients with peripheral neuropathy treated with phosphatidylcholin sodum is 65%, significantly higher than the control group's 38% (p<0.01).
Clinical Pharmacological Effects: Transformation from Basic Research to Clinical Application
Mechanim:
Relieve secondary brainless ischemia by increasing brainless blood flow and oxygen supply.
Inhibit glutamate excitotoxicity and reduce neuronal apoptosis.
Promote NGF synthesis and accelerate axonal regeneration.
Evidence:
A multicenter RCT involving 300 patients showed that the sodum phosphatidylcholin group shortened coma time by 2.3 days (95% CI 1.5-3.1) and improved GCS scores by 2.1 points (p<0.01).
Electroencephalogram (EEG) monitoring shows that mediation can reduce delta wave power by 40% and increase alpha wave power by 25%, indicating the recvery of brain electrical activity.
Mechanim:
Promote synaptic remodeling and enhance excitability in representative areas of the motor cortex.
Regulate the balance of DA and GABA in the basal ganglia region and alleviate muscle tone disorders.
Inhibit the release of inflammatory factors such as IL-1 β and TNF - α, and alleviate brain edema.
Evidence:
Meta analysis shows that the combination of phosphatidylcholin sodum can increase Barthel index by 15.6 points (95% CI 10.2-21.0) and Fugl Meyer score by 12.3 points (p<0.001).
Functional magnetic resonance imaging (fMRI) confirms that drugs can expand the activated volume of the affected motor cortex by 35% and promote cross hemispheric compensation.
Mechanim:
Enhance cholinergic transmission in the prefrontal cortex and improve working memory capacity.
Regulating the ability of NMDA receptors in the hippocampus and improving episodic memory encoding.
Inhibit the formation of A β fibers and reduce neuronal tangles.
Evidence:
After treatmen, the MMSE score of patients with vascular dementia increased by 2.8 points (p=0.02), while the ADAS Cog score decreased by 3.1 points (p=0.01).
Event related potentials (ERP) showed a 20ms shortened latency of P300, indicating an increase in information processing speed.
Mechanim:
Inducing NGF synthesis and activating Schwann cell proliferation.
Inhibit Nav1.3 sodum channel expression and reduce ectopic discharge.
Regulate the activation of spinal dorsal horn glial cells and block pain signal transmission.
Evidence:
After treatmen for patients with diabetes peripheral neuropathy, the improvement rate of nerve conduction velocity (NCV) was 68%, and the visual analogue score (VAS) decreased by 2.1 points (p<0.001).
Skin biopsy showed a 40% increase in intraepidermal nerve fiber density (IENFD), approaching normal levels.
Drug interactions and mediation monitoring
1. Synergistic effect
Mannitol:
Combination therapy for brainless edema can enhance the effect of reducing intracranial pressure (increasing the decrease in ICP by 30%).
Mecobalamin:
Jointly promotes peripheral nerve repair, increasing the improvement rate of NCV to 75%.
Donepezil:
Combined cholinergic enhancement effect, resulting in an additional 1.5 points increase in MMSE score.
2. Antagonistic effect
Levodopa:
Competitively inhibits choline uptake, requiring dosing at intervals of at least 2 hours.
Meclofenate:
Inhibits the transport of sodum phosphatidylcholin and reduces drug concentration in the brain by 30%.
Alcohol:
Enhances central excitability and increases the risk of insomnia and tremors.
3. Key points of mediation monitoring
Vital sign monitoring:
Measure blood pressure and heart rate before and 30 minutes after administration, and be alert for hypotension (systolic blood pressure<90mmHg) or tachycardia (>120 beats/minute).
01
Neurological assessment:
Perform daily GCS or NIHSS scoring to observe changes in consciousnes status.
02
Laboratory examination:
Long term use requires regular testing of liver ability (ALT, AST), kidney ability (blood creatinine, urea nitrogen), and electrolytes (K ⁺, Na ⁺).
03
Allergy history screening:
Inquire about drug allergy history before the first use of mediation, and conduct a skin test if necessary (although not a routine requirement, high-risk patients may consider it).
04
Citicoline sodium injection exhibits unique advantages in the treatmen of acute traumatic brain injury, stroke rehabilitation, and cognitive impairment through the synergistic effect of multiple targets and pathways. Its mechanim of action covers key links such as brainless vascular dynamics regulation, neurotransmitter balance, cell membrane repair, and energy metabolis optimization, forming a complete chain of evidence from molecular to clinical. In the future, with the development of nanotechnology and precision medicine, the clinical application of phosphatidylcholin sodum will be further expanded, providing more efficient and safe treatmen options for patients with neurological diseases.
Hot Tags: citicoline sodium injection, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale